Compass Pathways (NASDAQ:CMPS – Get Free Report) will likely be announcing its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect Compass Pathways to post earnings of ($0.3857) per share for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.
Compass Pathways (NASDAQ:CMPS – Get Free Report) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.15. On average, analysts expect Compass Pathways to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Compass Pathways Stock Down 3.7%
Shares of Compass Pathways stock opened at $10.85 on Wednesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.32 and a quick ratio of 3.32. Compass Pathways has a 1 year low of $3.92 and a 1 year high of $15.40. The firm’s 50-day moving average is $12.54 and its two-hundred day moving average is $9.08. The stock has a market cap of $1.46 billion, a price-to-earnings ratio of -3.44 and a beta of 2.47.
Wall Street Analysts Forecast Growth
Check Out Our Latest Report on Compass Pathways
Institutional Trading of Compass Pathways
Hedge funds have recently modified their holdings of the company. Corient Private Wealth LLC boosted its holdings in shares of Compass Pathways by 3.2% in the 4th quarter. Corient Private Wealth LLC now owns 38,438 shares of the company’s stock valued at $265,000 after buying an additional 1,200 shares in the last quarter. XTX Topco Ltd raised its stake in shares of Compass Pathways by 457.5% during the 4th quarter. XTX Topco Ltd now owns 56,786 shares of the company’s stock worth $392,000 after acquiring an additional 46,600 shares in the last quarter. Virtus Investment Advisers LLC raised its stake in shares of Compass Pathways by 56.8% during the 4th quarter. Virtus Investment Advisers LLC now owns 39,471 shares of the company’s stock worth $272,000 after acquiring an additional 14,297 shares in the last quarter. Squadron Capital Management LLC bought a new position in shares of Compass Pathways during the 4th quarter worth approximately $2,679,000. Finally, Toronto Dominion Bank lifted its position in Compass Pathways by 152.9% during the fourth quarter. Toronto Dominion Bank now owns 2,529,013 shares of the company’s stock valued at $17,447,000 after acquiring an additional 1,529,013 shares during the last quarter. 46.19% of the stock is owned by hedge funds and other institutional investors.
About Compass Pathways
Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.
Featured Stories
- Five stocks we like better than Compass Pathways
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Receive News & Ratings for Compass Pathways Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Pathways and related companies with MarketBeat.com's FREE daily email newsletter.
